Experts worry insulin getting too expensive for many in U.S. and worldwide

Eric Palmer Healthcare professionals are concerned that hormone insulin meds, often the key diabetes treatment, are getting too costly for many patients, even in the U.S. In developing ...

Bayer invests in U.S. growth to get it through its big transitions

Carly Helfand Plenty of Bayer's peers are focusing their expansion efforts outside the U.S., on emerging markets with more growth potential. But not the German pharma. Instead, ...

New data boosts Novo against Sanofi in insulin-market fight

Carly Helfand Novo Nordisk has some new data in hand that could help a safety advantage make its way onto the label of new drug Tresiba–and win it points against heavyweight ...

With a Duchenne MD patient struggling for life, little Akashi suspends study

John Carroll Nonprofit-backed Akashi Therapeutics has suspended a trial of its lead drug for Duchenne muscular dystrophy after a patient on the highest dose experienced "life-threatening ...

Glaxo weighs Qualcomm JV in quest to move ‘beyond the pill’

Carly Helfand Big Pharma companies–GlaxoSmithKline included–have been looking for ways to move "beyond the pill" to gain a technological leg up on their rivals. ...

Crippled by 2 deaths, Zafgen says obesity drug cut weight in PhIII

John Carroll With its clinical development program for a new obesity drug in limbo following the unexplained deaths of two patients, Zafgen reported today that the troubled Phase III ...

Eleven Bio faces cash crunch as lead drug flunks another PhIII

John Carroll FierceBiotech News

PTO shuts down Amgen’s Humira IP challenge

Carly Helfand Amgen has hit a potential snag in its quest to bring a biosimilar of AbbVie cash cow Humira to market. Thursday, the U.S. Patent and Trademark Office declined to review ...

FDA delays decision on Heron’s twice-rejected nausea drug

Damian Garde Heron Therapeutics, pushing to finally win approval for a long-delayed treatment for chemotherapy-induced nausea, will have to wait another month or so as the FDA has put ...

Cipla says top 50 drugs in development could bring in $30B

John Carroll Indian drugmaker Cipla said it currently has 200 drugs in development and that the top 50 of those drugs have the potential to earn the company more than $ 30 billion. FierceBiotech ...

Post-restructuring, Biogen’s top execs are back in the R&D talent hunt

John Carroll SAN FRANCISCO–Four months after Biogen swiftly slashed 880 jobs in a wrenching restructuring, the biotech trendsetter is back on a new hiring spree in research aimed ...

Shire CEO thinks he can beat $500M in postmerger cost savings

Emily Wasserman Shire may have clinched its $ 32 billion deal to buy Baxalta, but not everyone is breaking out the confetti. Some analysts aren't sold on the tie-up, saying they ...
Page 1 of 3412345...102030...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS